- Home
- LFT vs KPTI Comparison
LFT vs KPTI Comparison
Compare LFT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- KPTI
- Stock Information
- Founded
- LFT 2012
- KPTI 2008
- Country
- LFT United States
- KPTI United States
- Employees
- LFT N/A
- KPTI N/A
- Industry
- LFT Real Estate Investment Trusts
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- KPTI Health Care
- Exchange
- LFT Nasdaq
- KPTI Nasdaq
- Market Cap
- LFT 127.0M
- KPTI 121.2M
- IPO Year
- LFT N/A
- KPTI 2013
- Fundamental
- Price
- LFT $2.55
- KPTI $0.85
- Analyst Decision
- LFT Buy
- KPTI Strong Buy
- Analyst Count
- LFT 3
- KPTI 4
- Target Price
- LFT $2.50
- KPTI $5.00
- AVG Volume (30 Days)
- LFT 86.0K
- KPTI 857.1K
- Earning Date
- LFT 11-11-2024
- KPTI 10-31-2024
- Dividend Yield
- LFT 12.55%
- KPTI N/A
- EPS Growth
- LFT 162.49
- KPTI N/A
- EPS
- LFT 0.35
- KPTI N/A
- Revenue
- LFT $35,996,585.00
- KPTI $145,668,000.00
- Revenue This Year
- LFT N/A
- KPTI $6.41
- Revenue Next Year
- LFT N/A
- KPTI $11.85
- P/E Ratio
- LFT $7.32
- KPTI N/A
- Revenue Growth
- LFT 48.96
- KPTI N/A
- 52 Week Low
- LFT $1.91
- KPTI $0.62
- 52 Week High
- LFT $2.75
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- LFT 55.14
- KPTI 56.54
- Support Level
- LFT $2.38
- KPTI $0.82
- Resistance Level
- LFT $2.62
- KPTI $0.88
- Average True Range (ATR)
- LFT 0.07
- KPTI 0.07
- MACD
- LFT 0.01
- KPTI 0.00
- Stochastic Oscillator
- LFT 69.79
- KPTI 59.36
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.